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Cancer immunotherapy has clearly taken its place in the
clinic as one pillar of cancer care. Immune checkpoint
blockade, which unleashes the activity of pre-existing T
cells at the tumor site, is transforming cancer treatment.
The FDA approval of the cytotoxic T lymphocyte antigen-
4 (CTLA-4) antagonist ipilimumab for unresectable or
metastatic melanoma on March 25, 2011 forged a path for
the further clinical development of immune checkpoint
modulation. Building on its success, antagonists of the
programmed death-1 (PD-1) pathway have now been
approved for use in advanced melanoma, non-small cell
lung cancer (NSCLC), renal cell carcinoma, bladder cancer,
and Hodgkin’s disease. Blockade of the PD-1 pathway pro-
duces durable objective responses in 20–30 % of patients
with solid tumors, with clear activity in multiple other
cancer types as well [1]. This striking clinical success has
re-invigorated interest in cancer immunotherapy, pro-
moted the rapid growth of the immuno-oncology pipeline,
and accelerated the clinical development of treatment
strategies that engage the immune system to treat cancer.
Therapeutic cancer vaccines, designed to promote the
activation and expansion of T cells, have been studied in
the clinic since the late 1800’s with mostly negative
results. This lack of success has been attributed to both
suboptimal vaccine formulations, flawed clinical devel-
opment plans, and dominant mechanisms of immune
tolerance and suppression in the tumor microenviron-
ment that prevent T cell activity [2–4]. There was a
flash of hope for therapeutic cancer vaccines on April
29, 2010 when the FDA approved sipuleucel-T for the
treatment of asymptomatic or minimally symptomatic
castrate-resistant prostate cancer. Sipuleucel-T is a cel-
lular immunotherapy product composed of autologous
peripheral blood mononuclear cells (PBMC) obtained
by leukapheresis and activated with a recombinant fu-
sion protein that delivers the tumor antigen prostatic
acid phosphatase (PAP) linked to the immune-activating
cytokine granulocyte-macrophage colony-stimulating factor
(GM-CSF). The pivotal trial was a placebo-controlled mul-
ticenter trial that randomized 512 patients at a 2:1 ratio to
receive three infusions of sipuleucel-T or unactivated con-
trol PBMC over the course of 1 month. It demonstrated a
modest 4.1-month improvement in overall survival, where
the sipuleucel-T-treated and control groups had a median
overall survival of 25.8 and 21.7 months, respectively
(HR = 0.775, 95 % CI 0.61–0.098, p = 0.032) [5]. There
was no impact on progression free survival. Unfortu-
nately, the complexity of the manufacturing process,
the cost, and the rapidly changing landscape of prostate
cancer therapy led to slow uptake of sipuleucel-T and the
original manufacturer ultimately declared bankruptcy.
Despite these challenges, interest in cancer vaccines is
growing. Quoix and colleagues recently reported prom-
ising results of the Phase 2b portion of the TIME trial, a
Phase 2b/3 clinical trial testing the vaccine TG4010
combined with chemotherapy in patients with advanced
NSCLC [6]. TG4010 is a recombinant modified vaccinia
Ankara virus that delivers the tumor antigen mucin-1
(MUC-1) with the immune-activating cytokine interleukin-
2 (IL-2). The induction of an immune response specific for
MUC-1 is enhanced both by danger signals present in the
viral vector and by local expression of IL-2 at the vaccine
site. The Phase 2b/3 trial was based on promising results
of earlier randomized trials demonstrating the safety and
clinical activity of TG4010 in combination with chemo-
therapy in NSCLC [7, 8]. These trials identified a candidate
predictive biomarker: TrPAL, activated natural killer cells
triple positive for CD16, CD56, and CD69. A low baseline
level of TrPAL appeared to predict for TG4010 activity in
combination with chemotherapy; the 25 % of patients with
the highest TrPAL values did not benefit, whereas the 75 %
of patients with the lowest TrPAL levels did. High levels of
TrPAL are thought to suppress the induction of an adaptive
immune response by TG4010. This apparent conundrum
may be explained by the dual role of natural killer cells in
the regulation of adaptive immunity.
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The TIME trial is a randomized, double-blind, placebo-
controlled Phase 2b/3 trial that enrolls previously un-
treated patients with stage 4 NSCLC without a known
activating EGFR mutation and with MUC-1 expression in
at least 50 % of tumor cells [6]. In the Phase 2b portion,
222 patients were randomized 1:1 to receive 108
plaque-forming units (pfu) of TG4010 or placebo (the
formulation buffer of TG4010) from the initiation of
chemotherapy weekly for 6 weeks, and then every
3 weeks until disease progression. Randomized patients
were stratified according to the baseline level of TrPAL
(≤ or > the upper limit of normal (ULN)). Chemother-
apy was a platin-based doublet given at standard doses
for up to 6 cycles, and bevacizumab and maintenance
treatment with pemetrexed or erlotinib were permitted
as clinically indicated. The primary endpoint was PFS
assessed every 6 weeks to validate the predictive value
of the TrPAL biomarker. For the population as a whole,
the median PFS for the TG4010 and placebo groups
was 5.9 months (95 % CI 5.4–6.7) and 5.1 months
(95 % CI 4.2–5.9) respectively (HR = 0.74, 95 % CI
0.55–0.98, one-sided p = 0.019). The treatment effect of
adding TG4010 to chemotherapy was delayed, consist-
ent with reported data with other cancer immunother-
apies like sipuleucel-T and ipilimumab [5, 9]. The study
validated the association of the TrPAL biomarker with
benefit in patients with a TrPAL value ≤ ULN, but not the
association of the TrPAL biomarker with lack of benefit in
patients with a TrPAL value > ULN. As this threshold
corresponded to the first 3 quartiles (Q3) of the patient
distribution (75 %) in the earlier Phase 2b trial [7], a pre-
specified analysis demonstrated the patients with TrPAL
values ≤Q3 had a significant improvement in PFS, but
those with TrPAL values >Q3 did not. Based on these data
supporting an improvement in PFS with TG4010 with
chemotherapy relative to control, and the predictive value
of a low baseline level of TrPAL, the study continues to
fully evaluate the clinical activity of TG4010 and to valid-
ate TrPAL as a companion predictive biomarker in this
patient population.
Importantly, the TIME trial evaluated multiple
biomarkers. First, it required expression of the tumor
antigen MUC-1 in at least 50 % of tumor cells for eligi-
bility. This is important as MUC-1 is the target of the
vaccine-induced T cell response. Ensuring adequate
levels of expression of the target antigen by the tumor is
thus critical for success. Although not reported here, an
association between the clinical activity of TG4010 and
MUC-1-specific T cells in NSCLC patients has been
reported in an earlier trial (8). Second, it evaluated the
TrPAL biomarker as an additional predictive biomarker
of benefit with the combination of TG4010 and chemo-
therapy. The investigators demonstrated that low levels
of TrPAL appear to predict clinical benefit from TG4010
combined with chemotherapy. Third, in a post-hoc ex-
ploratory analysis, the investigators evaluated expression
of PD-L1 in available pretreatment tumor specimens;
160 (72 %) patients were assessable for tumor cell PD-
L1 expression, and 137 (62 %) patients were assessable
for PD-L1 expression in infiltrating immune cells. They
noted a significant improvement in PFS with TG4010
and chemotherapy relative to the control group in
patients with a low level of PD-L1 expression in the im-
mune cell infiltrate, but not in those with higher levels
of PD-L1 expression in the immune cell infiltrate (HR
0.61 [95 % CI 0.39–0.96]; p = 0.015). The level of PD-L1
expression by tumor cells appeared to make no differ-
ence. This finding raises the interesting possibility that
adding a PD-1 or PD-L1 antagonist to block intratu-
moral immune suppression in patients with higher levels
of PD-L1 expression at the tumor site could expand the
number of patients who respond to TG4010 combined
with chemotherapy. Prospective clinical trials will be
required to test these hypotheses.
Where are we with simple predictive biomarkers in can-
cer immunotherapy? The PD-1 antagonist pembrolizumab
was granted accelerated approval by the FDA on October
2, 2015 for the second line treatment of advanced PD-L1+
NSCLC together with the companion diagnostic PD-L1
IHC22C3 pharmDx test. This approval was based on
objective response rates of 45 % in PD-L1+ patients rela-
tive to 19 % in all patients enrolled on the trial [10].
Nivolumab and atezolizumab also appear to have greater
activity in tumors that express PD-L1 [11–15], and nivolu-
mab is also FDA-approved for the second line therapy of
NSCLC. Separately, a diagnostic test for PD-L1 expres-
sion, the PD-L1 IHC 28-8 Pharm Dx test, was approved
to help physicians select patients more likely to benefit
from PD-1 blockade with nivolumab. Thus, PD-L1 expres-
sion within the tumor microenvironment appears to
enrich for responders to antagonists of the PD-1 pathway,
but is an imperfect biomarker due in part to geographic
variability in expression within a given tumor and across
tumor metastases, and dynamic changes in PD-L1 expres-
sion over time. Microsatellite instability (MSI) has more
recently been proposed as a predictive biomarker of
response to pembrolizumab based on response rates of 40
and 0 % in mismatch repair deficient and proficient
tumors, respectively [16]. This is thought to reflect a
higher load of neoantigens generated by mutation in the
mismatch repair deficient tumors, rendering them more
immunogenic. These findings are being further explored
and validated in larger trials. With these advances, we are
beginning to develop informative predictive biomarkers of
response to cancer immunotherapies. An association
between the baseline level of TrPAL and the response of
MUC-1+ NSCLC to TG4010 and chemotherapy, if
validated in the Phase 3 portion of the TIME trial, could
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add another promising predictive biomarker to our
toolbox. Companion predictive biomarkers of response
and resistance to cancer immunotherapies are important
to identify the patients most likely to respond, thus avoid-
ing unnecessary toxicity and cost in patients unlikely to
benefit. Thus, elucidating reliable biomarkers of response
and resistance to established and emerging cancer
immunotherapies should continue to be a high priority for
clinical development.
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